J Cancer 2021; 12(14):4362-4371. doi:10.7150/jca.57076


Receptor-interacting protein in malignant digestive neoplasms

Lilong Zhang, Wenyi Guo, Jia Yu, Chunlei Li, Man Li, Dongqi Chai, Weixing Wang, Wenhong Deng

Department of General Surgery, Renmin Hospital of Wuhan University, Jiefang Road 238, Wuhan, Hubei 430060, China.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Zhang L, Guo W, Yu J, Li C, Li M, Chai D, Wang W, Deng W. Receptor-interacting protein in malignant digestive neoplasms. J Cancer 2021; 12(14):4362-4371. doi:10.7150/jca.57076. Available from https://www.jcancer.org/v12p4362.htm

File import instruction


A deep and comprehensive understanding of factors that contribute to cancer initiation, progression, and evolution is of essential importance. Among them, the serine/threonine and tyrosine kinase-like kinases, also known as receptor interacting proteins (RIPs) or receptor interacting protein kinases (RIPKs), is emerging as important tumor-related proteins due to its complex regulation of cell survival, apoptosis, and necrosis. In this review, we mainly review the relevance of RIP to various malignant digestive neoplasms, including esophageal cancer, gastric cancer, colorectal cancer, hepatocellular carcinoma, gallbladder cancer, cholangiocarcinoma, and pancreatic cancer. Consecutive research on RIPs and its relationship with malignant digestive neoplasms is required, as it ultimately conduces to the etiology and treatment of cancer.

Keywords: Receptor Interacting Proteins, malignant digestive neoplasms, Therapeutics, Necroptosis